NCT00197132CompletedPhase 3
A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- Forearm blood flow
Study Overview
Brief Summary
Fluid management study in patients with insulin resistance.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 30 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •BMI 27-36 kg/m2 inclusive and at least two additional features of the metabolic syndrome or a first degree relative with a history of type 2 diabetes mellitus. BMI = Weight/height², (where weight is in kg, height in m).
- •Male or female aged 30 to 65 years, inclusive, at screening.
- •Female subjects must be post-menopausal (i.e. >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant Depo-Provera) or intra-uterine devices (IUD) (a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study treatment.
- •Willing and able to provide a signed and dated written informed consent.
Exclusion Criteria
- •Subjects with type 2 diabetes mellitus defined as an HbA1c level >6.5% or a fasting plasma glucose of > 7.0 mmol/L. If fasting plasma glucose is between 6.1 and 7.0 mmol/L then a 75 g oral glucose test will be performed to exclude diabetes mellitus.
- •Subjects who have initiated lipid lowering therapy within the last 6 months and subjects who have increased the dose of these therapies within the last 3 months prior to study start.
- •Subjects who are taking Non Steroidal Anti-inflammatory Drugs, fibrates, anticoagulants or cardiovascular medications (β-blockers, nitrates, calcium antagonists, ACE inhibitors, angiotensin II antagonists, alpha blockers, diuretics, centrally acting anti-hypertensives, directly acting antihypertensives e.g., diazoxide, digoxin, anti-arrhythmics) and are unable to stop these medications for the duration of the study.
- •Exposure to a thiazolidinedione (TZD) or other PPAR-γ agonist (e.g. rosiglitazone, troglitazone, pioglitazone, G1262570) within the last 4 months or participation in a clinical study involving a TZD or PPAR-γ agonist.
- •Subjects who have required the use of any anti-diabetic medication at any time.
- •Use of any investigational drug within 30 days preceding the first dose of medication at the start of the study.
- •Subjects with a documented history of significant hypersensitivity (e.g. difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones or PPAR-γ agonists.
- •Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg or receiving antihypertensive therapy.
- •Subjects with unstable or severe angina (requiring continual therapy) or congestive heart failure.
- •Presence of clinically significant hepatic disease.
- •Clinically significant anaemia.
- •Subjects with creatinine clearance <40 mL/min.
- •Women who are lactating, pregnant or planning to become pregnant during the course of the study.
- •Alcohol or drug abuse within the last 6 months.
Outcomes
Primary Outcomes
Forearm blood flow
Secondary Outcomes
- Insulin sensitivity, plasma volume, transcapillary escape rate, inhibition to vasodialtory response, changes in cardiac output, plasma catecholamine levels, changes in plasma hormone/markers of vascular permeability, safety and tolerability.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.Neuropathy, DiabeticNCT00422955GlaxoSmithKline36
Recruiting
Not Applicable
Case control study of insulin resistance and metabolic syndrome in pimples among men of age more than 20CTRI/2018/03/012532K S Hegde medical academy
Recruiting
Not Applicable
A study on insulin technique of diabetic patientsdiabetes mellitusJPRN-UMIN000033698Takagi Hospital50
Completed
Phase 3
A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with Cystic Fibrosis-Related Diabetes1001842410038686Cystic FibrosisNL-OMON38078HagaZiekenhuis25
Active, not recruiting
Not Applicable
A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes - Insulin therapy and adjuvant metformin in CFRDCystic fibrosis-related diabetesMedDRA version: 9.1Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)MedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2009-009875-37-NLStaf Longziekten25